The Dasatinib CL controversy continues to rage, with two government agencies locked in a clear tussle. While the Health Ministry is keen on activating the section 92 compulsory licensing (CL) route, the DIPP appears more cautious on this count. In the meantime, the Union for Affordable Cancer Treatment (UACT) petitioned the USTR head, Michael Froman citing concerns that the US pressure on India and the announcement of an out-of-cycle review of India’s status has resulted in the Indian Government shelving...
↧